Llwytho...
PARP inhibitors for Homologous Recombination- Deficient Prostate Cancer
INTRODUCTION: Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant di...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Expert Opin Emerg Drugs |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088797/ https://ncbi.nlm.nih.gov/pubmed/29595348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2018.1459563 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|